| Clinical outcomes of escalation vs early intensive disease-modifying therapy in patients with multiple sclerosis K Harding, O Williams, M Willis, J Hrastelj, A Rimmer, F Joseph, ... JAMA neurology 76 (5), 536-541, 2019 | 323 | 2019 |
| Clinical outcomes of escalation vs early intensive disease-modifying therapy in patients with multiple sclerosis. JAMA Neurol. 2019 Feb; 76 (5): 536-41 K Harding, O Williams, M Willis, J Hrastelj, A Rimmer, F Joseph Přejít k původnímu zdroji... Přejít na PubMed, 2018 | 19 | 2018 |
| Multiple sclerosis: long‐term outcomes in ethnic minorities. Analysis of a UK population‐based registry MO Alsaeed, KE Harding, OH Williams, MD Willis, J Hrastelj, ... European Journal of Neurology 25 (4), 701-704, 2018 | 14 | 2018 |
| CSF-resident CD4+ T-cells display a distinct gene expression profile with relevance to immune surveillance and multiple sclerosis J Hrastelj, R Andrews, S Loveless, J Morgan, SM Bishop, NJ Bray, ... Brain communications 3 (3), fcab155, 2021 | 13 | 2021 |
| Ice bucket challenge bears fruit for amyotrophic lateral sclerosis J Hrastelj, NP Robertson Journal of neurology 263, 2355-2357, 2016 | 10 | 2016 |
| Clinical outcomes of escalation vs early intensive disease-modifying therapy in patients with multiple sclerosis. JAMA Neurol 76 (5): 536–541 K Harding, O Williams, M Willis, J Hrastelj, A Rimmer, F Joseph, ... | 7 | 2019 |
| Clinical outcomes of escalation vs early intensive diseasemodifying therapy in patients with multiple sclerosis. JAMA Neurol 76: 536–541 K Harding, O Williams, M Willis, J Hrastelj, A Rimmer, F Joseph, ... | 5 | 2019 |
| Genetics of disease severity in multiple sclerosis, Alzheimer’s disease, and Huntington’s disease: rejuvenating genome-wide association studies J Hrastelj, N Robertson Journal of Neurology 264, 2040-2042, 2017 | 5 | 2017 |
| A role for the Epstein–Barr virus in multiple sclerosis aetiology? J Hrastelj, NP Robertson Journal of Neurology 269 (7), 3962-3963, 2022 | 3 | 2022 |
| Hypercalcaemia mimicking Huntington’s disease: lessons learned from delayed diagnosis J Hrastelj, D McLauchlan, A Rosser, C Clenaghan Journal of the Royal College of Physicians of Edinburgh 44 (4), 286-288, 2014 | 3 | 2014 |
| Modelling disease progression of Multiple Sclerosis in a South Wales cohort EC Uzochukwu, KE Harding, J Hrastelj, KL Kreft, P Holmans, ... Neuroepidemiology 58 (3), 218-226, 2024 | 2 | 2024 |
| Improving survival in amyotrophic lateral sclerosis: future treatments in a modern service J Hrastelj, NP Robertson Journal of neurology 262, 1791-1793, 2015 | 2 | 2015 |
| Path from discovery to recovery: therapeutic and diagnostic advances in Alzheimer's dementia AM Saw, J Hrastelj, NP Robertson Journal of Neurology 270 (8), 4151-4153, 2023 | 1 | 2023 |
| Vaccine-induced immune thrombosis and thrombocytopaenia: incidence, mechanism and treatment J Hrastelj, NP Robertson Journal of Neurology 268, 4396-4397, 2021 | 1 | 2021 |
| Gene expression regulation in immune cell dysfunction in multiple sclerosis J Hrastelj Cardiff University, 2023 | | 2023 |
| Advances in the genetics of stroke risk and recovery SN Majumder, J Hrastelj, NP Robertson Journal of Neurology 270 (1), 590-591, 2023 | | 2023 |
| CSF-resident CD4+ T-cells display a distinct gene expression profile relevant to multiple sclerosis J Hrastelj, R Andrews, S Loveless, J Morgan, M Bishop, N Bray, ... Journal of Neurology, Neurosurgery and Psychiatry 93 (6), A93-A93, 2022 | | 2022 |
| Socioeconomic status in neurological disorders: a modifiable risk factor? J Hrastelj, NP Robertson Journal of Neurology 269 (6), 3385-3386, 2022 | | 2022 |
| 158 CSF T-cell counts in multiple sclerosis diagnosis and prognosis J Hrastelj, M Willis, M Bishop, S Loveless, E Tallantyre, N Robertson Journal of Neurology, Neurosurgery and Psychiatry 90 (12), e43, 2019 | | 2019 |
| WED 139 Gene expression regulation in CD4+ t-cell dysfunction in ms H James, B Nicholas, W Nigel, R Neil Journal of Neurology, Neurosurgery & Psychiatry 89 (10), A16-A16, 2018 | | 2018 |
